Special Issue "PI3 Kinase Inhibitors"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (30 June 2012)
Dr. Philip Thompson
Medicinal Chemistry and Drug Action, Monash Institute of Pharmaceutical, Sciences, Monash University, Parkville 3052, Australia
Phosphoinositide 3-kinases (PI3K) are important cell signalling enzymes, generating key second messengers that regulate a myriad of cellular functions. In recent years, potential applications for inhibitors have emerged in the treatment of cancer, cardiovascular disease, inflammatory diseases and autoimmune diseases. This special issue hopes to highlight the challenges and lessons learned in going from "hit to lead" and "lead to candidate" when developing targets for PI3K. Articles that deal with the concepts and results of specific strategic choices in PI3K inhibitor pharmaceutical development are encouraged. These include design approach (eg library screening, structure based design), isoform selectivity, scaffold selection, ADME properties or in vitro/in vivo models. In this issue, I hope novel contributions can be made to the medicinal chemistry knowledge base with original papers or critical reviews.
Dr. Philip Thompson
- PI3 kinase
- cell signaling
- cancer therapeutics
- lipid kinase
- immune disease
Review: The Phosphatidylinositol 3-Kinase/mTor Pathway as a Therapeutic Target for Brain Aging and Neurodegeneration
Pharmaceuticals 2011, 4(8), 1070-1087; doi:10.3390/ph4081070
Received: 12 May 2011; in revised form: 22 July 2011 / Accepted: 28 July 2011 / Published: 4 August 2011| Download PDF Full-text (550 KB) | Download XML Full-text
Pharmaceuticals 2012, 5(11), 1236-1264; doi:10.3390/ph5111236
Received: 27 September 2012; in revised form: 7 November 2012 / Accepted: 14 November 2012 / Published: 20 November 2012| Download PDF Full-text (325 KB) | Download XML Full-text
Last update: 4 March 2014